SDT-011 / Yissum Research Development Company, EMRIS Pharma, Hadassah Medical Organization - LARVOL DELTA

PREVENTING SKIN TOXICITIES INDUCED BY NOVEL BISPECIFIC EGFR INHIBITORS BY TOPICALLY BLOCKING DRUG-RECEPTOR INTERACTION (MASCC-ISOO 2025) - "In our previous work, we developed a compound (SDT-011) and method to prevent "on-target" skin toxicity by topically blocking the drug-receptor interactions of cetuximab and panitumumab at the site of toxicity...Additionally, in silico docking experiments provided insights into SDT-011's mechanism of action in blocking amivantamab, petosemtamab, and izalontamab...Conclusions Our innovative topical approach aims to prevent skin toxicities caused by EGFRi monoclonal and bispecific antibodies by blocking the initial trigger causing skin damage. By mitigating skin toxicities associated with bispecific EGFR inhibitors, SDT-011 could enhance treatment adherence and improve patients' quality of life, ultimately optimizing cancer therapy outcomes."

Oncology • ERBB3

Preventing skin toxicities induced by EGFR inhibitors by topically blocking drug-receptor interaction (MASCC-AFSOS-ISOO 2024) - "Results By binding to EGFR, SDT-011 effectively modulates the affinity of established EGFR inhibitors such as cetuximab and panitumumab to EGFR, while reactivating EGFR signaling. Conclusions Our innovative approach not only holds promise in reducing the burden of skin toxicity induced by EGFR inhibitors but also represents a significant advancement in the field of cancer therapy. This novel intervention has the potential to revolutionize the management of skin toxicities, ensuring both enhanced treatment outcomes and an improved quality of life for affected individuals.This research was published in Science Translational Medicine journal: https://www.science.org/doi/10.1126/scitranslmed.abo0684"

Oncology